Forum Financial Management LP Invests $217,000 in Masimo Co. (NASDAQ:MASI)

Forum Financial Management LP acquired a new stake in shares of Masimo Co. (NASDAQ:MASI) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,314 shares of the medical equipment provider’s stock, valued at approximately $217,000.

Several other large investors also recently added to or reduced their stakes in the stock. Jones Financial Companies Lllp bought a new stake in shares of Masimo during the fourth quarter valued at approximately $27,000. UMB Bank n.a. increased its holdings in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont bought a new stake in Masimo during the 4th quarter valued at $33,000. Blue Trust Inc. lifted its holdings in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Trading Up 1.9 %

NASDAQ:MASI opened at $152.07 on Wednesday. The firm has a 50 day moving average of $166.89 and a 200 day moving average of $165.11. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 104.88 and a beta of 1.28.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million during the quarter, compared to analysts’ expectations of $593.35 million. As a group, sell-side analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Insider Transactions at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This trade represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.70% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on MASI shares. Wells Fargo & Company lifted their price objective on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Raymond James boosted their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Piper Sandler increased their price objective on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.